论文部分内容阅读
目的观察呋塞米联合多巴胺微量泵入治疗顽固性心力衰竭的疗效、安全性及对患者血浆氨基末端脑钠肽前体(NT-proBNP)浓度的影响。方法将100例顽固性心力衰竭患者随机分为治疗组和对照组,对照组给予常规治疗,治疗组在对照组基础上加用呋塞米与多巴胺联合微量泵入,观察10 d,对两组的心功能改善、症状改善及心脏彩超进行对比,测6分钟步行试验(6MWT),并采用ELISA法对两组患者治疗前后血浆NT-proBNP进行测定。结果治疗组总有效率90%,显效率72%,治疗后左室射血分数(LVEF)显著高于对照组(P<0.05);6分钟步行距离增加;治疗组治疗后血浆NT-proBNP水平显著低于对照组(P<0.05)。结论呋塞米与多巴胺联合微量泵入在治疗顽固性心力衰竭中有重要意义,血浆NT-proBNP水平在心力衰竭治疗疗效评价中有较高敏感性。
Objective To observe the efficacy and safety of furosemide and dopamine micropump in the treatment of refractory heart failure and its effect on the concentration of plasma NT-proBNP in patients. Methods 100 patients with refractory heart failure were randomly divided into treatment group and control group. The control group was given routine treatment. The treatment group was treated with furosemide plus dopamine in combination with micro-pump on the basis of the control group. After 10 days of treatment, (6MWT). The plasma NT-proBNP levels in both groups before and after treatment were measured by ELISA. Results The total effective rate was 90% and the effective rate was 72% in the treatment group. The LVEF was significantly higher in the treatment group than in the control group (P <0.05), and the walking distance was increased in 6 minutes. After treatment, the plasma NT-proBNP level Significantly lower than the control group (P <0.05). Conclusions Furosemide and dopamine combined with micro-pump in the treatment of refractory heart failure is of great significance, plasma NT-proBNP levels in the treatment of heart failure have a higher sensitivity.